How will AI-first drug design transform human health?

AlphaFold’s impact on the research world has been astronomical. At ELRIG’s Drug Discovery 2025 (21–22 October; Liverpool, UK), we had the opportunity to speak with Miles Congreve (left), Chief Scientific Officer at Isomorphic Labs (IsoLabs; London, UK), to learn just how paradigm-shifting an AI-first drug discovery company can be. Miles joined IsoLabs 3.5 years ago, while the fledgling company founded by Nobel laureate and Google DeepMind (London, UK) founder Demis Hassabis had only 15 employees, to help build an AI-first drug discovery platform originally inspired by AlphaFold technologies for protein folding. Since he joined, the company has grown to over...